Will Public Health England lead research?  by McCarthy, Mark
Comment
2232 www.thelancet.com   Vol 386   December 5, 2015
Between 1990 and 2013, mortality rates in southeast 
regions of England fell below those of 18 comparison 
countries, whereas mortality rates in Scotland and 
Northern Ireland remained higher than all comparison 
countries except the USA. This headline can be gleaned 
from today’s detailed report by Public Health England 
(PHE) and the Global Burden of Disease study (GBD) in 
The Lancet.1 There are some caveats: analysis by region for 
the other 18 countries would also show a range around 
the national average; and the diﬀ erences in mortality 
were greater for men than for women. England has 
lower mortality rates from self-harm and road injury, but 
higher rates of liver disease and mental disorders related 
to alcohol misuse, compared with the other countries. 
Regional mortality rates in England correlate closely with 
the national index of deprivation (the components of 
which are chosen to amplify such variation), yet many 
non-fatal causes of disability, including low back and 
neck pain, anxiety disorders, sense-organ diseases, and 
breast cancer, show little regional variation. With the 
lengthening life-span of the population, overall levels of 
disability also remained broadly unchanged, indicating 
the continued necessity for health care.
Welcomed by The Lancet,2 the UK Department 
of Health in 2013 drew on the GBD study data for 
the new preventive health strategy for England, 
Living Well for Longer.3 The strategy set a political 
“ambition for England to have amongst the lowest 
rates of premature mortality in Europe” but focused 
on cancer, heart, stroke, respiratory, and liver disease; 
the existing low rates for injuries and self-harm and 
the prevalence of disabilities are not mentioned. Yet in 
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and can be more responsive to their populations than 
central government. The Zero TB Cities Project will 
provide independent funding in addition to country 
resources. Chennai in India and Lima in Peru are the ﬁ rst 
cities to take part and progress will be assessed at 3-year 
intervals. The goal is to help communities move to zero 
deaths from tuberculosis in their own way, and create 
“islands of elimination”, which will hopefully reverse the 
overall tuberculosis epidemic. 
The ﬁ nal Series paper by Katrina Ortblad and colleagues7 
reminds us that tuberculosis is the quintessential disease 
of poverty in modern times. It is a result of poverty and is 
itself a driver of poverty. To date, interventions to tackle 
tuberculosis have largely been biomedical. But other risk 
factors, such as malnutrition, overcrowding, and poor 
health services, also need to be addressed. The Sustainable 
Development Goals oﬀ er an opportunity to rethink the 
ﬁ ght against tuberculosis and to move to a more biosocial 
model that focuses not only on supply side interventions 
but also on demand side interventions at the individual 
level—for example, cash transfers and microcredit—to 
address the social determinants of this disease.
This Lancet Series is launched at the inauguration of 
the Harvard Medical School Center for Global Health 
Delivery—Dubai. The aim of this new centre is to 
promote research that will address the health delivery 
gap. Tuberculosis will be one of the disease areas of 
focus. We hope this Series will be a springboard that 
can help shift the global tuberculosis epidemic from 
incremental annual improvements to an accelerating 
global movement for tuberculosis elimination. 
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2013, the UK Government also transferred public health 
services from the National Health Service (NHS) into 
152 higher-tier local authorities,4 whereas the national 
communicable disease control service was recast as 
PHE with a remit across all diseases and injury. How will 
public health work alongside the NHS?
GBD has created a comprehensive resource of 
epidemiological data and has quantiﬁ ed estimates 
of attributable risk for mortality and disability. 
However, the causal pathways determining health, 
which population interventions are working, and in 
what contexts—for disability as well as for premature 
mortality—also need to be better understood. Why 
has London, with a higher deprivation index and more 
migration than other English regions, seen most 
improvement in mortality? Why do disability rates, 
some with relatively imprecise diagnoses, show less 
social variation than mortality? How do national policies 
aﬀ ect personal health behaviours, and to what extent 
are national mortality trends a cohort eﬀ ect from past 
policies? How do diﬀ erent economic priorities and 
characteristics of health-care provision across European 
countries aﬀ ect mortality and disability?
In August, 2015, PHE published a strategy for research, 
translation, and innovation.5 The “Priority One” objective 
of the strategy is to “focus researchers in PHE and 
elsewhere on research questions relevant to the evidence 
needed for public health”. The UK has a conﬁ dent 
strategy for research in the life sciences,6 promoting 
genomics, drug development, and medical technology. 
Funding for patient research through the Department of 
Health, Medical Research Council, Wellcome Trust, and 
medical charities is also substantial, but public health is 
only a small part of these medical research budgets.7,8
In a recent Lancet Comment about research using 
UK Biobank, Thompson and Willeit9 suggested that 
“the challenge lies in how changes can be achieved 
rather than in removing any uncertainty in scientiﬁ c 
understanding”. Further knowledge is needed of which 
interventions work in which contexts, how to scale 
them up, and what the eﬀ ects will be.10 Studies can 
draw on NHS big data and disease registers, investigate 
organisational changes and innovation in the health 
systems, and make longitudinal assessments of the 
eﬀ ects of social change, national policies, and local 
practice (the Public Health Practice Evaluation Scheme 
is a relevant start). Much better systems are also needed 
to provide evidence of the consequences of decisions: 
as clinicians see patient outcomes in a matter of days, 
and ﬁ nance oﬃ  cers see monthly spending, so public 
health practice needs to show eﬀ ects at population-level 
through real-time measures of social change, policy 
contexts, and programme implementation.
Determined coordination of an integrated, long-term 
budget for health research and innovation is required to 
match the dynamism that health metrics have generated 
and to develop a body of health knowledge comparable 
with clinical practice. The PHE study1 has more than 
60 UK authors, with almost as many aﬃ  liations, and 
shows the substantial UK capability to undertake 
research across a wide range of diseases and conditions, 
without commercial interests, patents, or spin-oﬀ 
companies. Can PHE bring all the partners together to 
achieve high-quality research on public health practice?
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The year 2015 marks the end of the era of the 
Millennium Development Goals (MDGs) and the 
beginning of implementation of the Sustainable 
Development Goals (SDGs). For child survival, which is 
the fourth goal of the MDGs and an important proposed 
indicator for the SDG health goal, 2015 is a crucial time 
to take stock of national, regional, and global progress. 
In The Lancet, Danzhen You and colleagues,1 on behalf 
of the UN Inter-agency Group for Child Mortality 
Estimation (UN IGME), estimate under-5 mortality 
levels and trends for 1990–2015, and project how these 
rates will change up to 2030 in various hypothetical 
scenarios. These estimates are invaluable in evaluating 
progress toward MDG 4 and informing the SDG process.
You and colleagues report1 that global under-5 
mortality has declined remarkably since 1990, from 
90·6 deaths per 1000 livebirths (90% uncertainty 
interval 89·3–92·2) to 42·5 deaths per 1000 livebirths 
(40·9–45·6) in 2015, with acceleration after 2000. Two 
regions, east Asia and the Paciﬁ c, and Latin America and 
the Caribbean, achieved the ambitious MDG 4 target of 
a two-thirds reduction in under-5 mortality. All other 
regions at least halved their under-5 mortality rates. 
Even in regions that did not achieve the target, many 
low-income and lower-middle-income countries did, 
such as Ethiopia, Eritrea, Liberia, Madagascar, Malawi, 
Mozambique, Niger, Rwanda, Tanzania, and Uganda. 
The ways these countries were able to achieve this level 
of reduction deserve careful study. In-depth case studies, 
such as Countdown to 2015 exercises in Niger and 
Tanzania,2,3 are powerful tools to disentangle the complex 
interplay between socioeconomic context, national 
policy, health system and ﬁ nancing, and implementation 
of life-saving interventions to gain insights into country 
successes and challenges. For example, in Niger almost 
90% of the decline in child mortality from 1998 to 2009 
was attributed to introduction of insecticide-treated 
bednets, improvements in nutritional status including 
vitamin A supplementation, treatment of malaria, 
pneumonia, and diarrhoea, and vaccinations, 
yet with little increase in maternal and newborn 
interventions, mortality in the neonatal period did not 
signiﬁ cantly decrease.2
If the current trends continue, sub-Saharan Africa 
could be home to about three-ﬁ fths of global under-5 
deaths in 2030 due to persistent high fertility and high 
child mortality in many countries.1,4 Global child survival 
and family planning communities will need to join 
forces to focus on sub-Saharan Africa where the dual 
challenges are to make contraception more accessible 
and to deliver child survival interventions.
You and colleagues1 focused on under-5 and infant 
mortality, but did not consider neonatal mortality. The UN 
IGME in a separate report estimated that 45% of under-5 
deaths occurred in the neonatal period in 2015.5 For 
1990–2015, mortality rates of children aged 1–59 months 
decreased much faster than those in neonates. Given the 
high burden and a slower rate of reduction of neonatal 
mortality, achieving new targets for child survival will 
increasingly depend on addressing neonatal causes of 
death. Stronger attention will need to be paid to the 
continuum of care, from adolescent girls and women 
before and during pregnancy, to newborn babies.
Aﬀ ordable proven interventions are available 
to reduce the burden of major causes of under-5 
mortality.6 Widescale implementation of case 
management of pneumonia and diarrhoea and scaling 
up of Haemophilus inﬂ uenzae type B, pneumococcus, 
and rotavirus vaccines will further reduce the burden of 
deaths owing to childhood pneumonia and diarrhoea.7 
In addition to insecticide-treated bednets and quality 
assured artemisinin-based combination therapies, 
the recently approved malaria vaccine holds potential 
for further reduction of malaria.8,9 Addressing major 
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